EP4157872A1 - Zusammensetzungen mit einem antikörper gegen den interleukin-6-rezeptor zur behandlung von rheumatoider arthritis und verfahren zur verwendung davon - Google Patents
Zusammensetzungen mit einem antikörper gegen den interleukin-6-rezeptor zur behandlung von rheumatoider arthritis und verfahren zur verwendung davonInfo
- Publication number
- EP4157872A1 EP4157872A1 EP21729026.1A EP21729026A EP4157872A1 EP 4157872 A1 EP4157872 A1 EP 4157872A1 EP 21729026 A EP21729026 A EP 21729026A EP 4157872 A1 EP4157872 A1 EP 4157872A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- subject
- administered
- rheumatoid arthritis
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title abstract description 36
- 238000011282 treatment Methods 0.000 title description 36
- 102000010781 Interleukin-6 Receptors Human genes 0.000 title description 7
- 108010038501 Interleukin-6 Receptors Proteins 0.000 title description 7
- 229950006348 sarilumab Drugs 0.000 claims description 73
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 62
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- 230000009266 disease activity Effects 0.000 claims description 37
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims description 33
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 33
- 229960000485 methotrexate Drugs 0.000 claims description 33
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 21
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 14
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 14
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 14
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 14
- 229960000681 leflunomide Drugs 0.000 claims description 14
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 14
- 229960001940 sulfasalazine Drugs 0.000 claims description 14
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 14
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 8
- 239000004012 Tofacitinib Substances 0.000 claims description 6
- 229950000971 baricitinib Drugs 0.000 claims description 6
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims description 6
- 229960001350 tofacitinib Drugs 0.000 claims description 6
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 6
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 229950000088 upadacitinib Drugs 0.000 claims description 5
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 4
- 229940125644 antibody drug Drugs 0.000 claims description 4
- 102000052611 human IL6 Human genes 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 abstract description 48
- 239000000427 antigen Substances 0.000 abstract description 41
- 108091007433 antigens Proteins 0.000 abstract description 41
- 102000036639 antigens Human genes 0.000 abstract description 41
- 230000027455 binding Effects 0.000 abstract description 40
- 239000012634 fragment Substances 0.000 abstract description 31
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 abstract description 21
- 102000052623 human IL6R Human genes 0.000 abstract description 21
- 208000024891 symptom Diseases 0.000 abstract description 15
- 230000006872 improvement Effects 0.000 description 30
- 239000003435 antirheumatic agent Substances 0.000 description 29
- 238000011269 treatment regimen Methods 0.000 description 25
- 210000001503 joint Anatomy 0.000 description 22
- 108010074051 C-Reactive Protein Proteins 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 210000004602 germ cell Anatomy 0.000 description 19
- 230000036407 pain Effects 0.000 description 19
- 230000036541 health Effects 0.000 description 17
- 230000004044 response Effects 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 15
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 102100032752 C-reactive protein Human genes 0.000 description 12
- 206010023232 Joint swelling Diseases 0.000 description 12
- 239000000090 biomarker Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 206010003246 arthritis Diseases 0.000 description 9
- 238000009097 single-agent therapy Methods 0.000 description 9
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 9
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 9
- 239000004475 Arginine Substances 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 8
- 229940090047 auto-injector Drugs 0.000 description 8
- 239000008366 buffered solution Substances 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 229940068977 polysorbate 20 Drugs 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 230000004630 mental health Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 108700028909 Serum Amyloid A Proteins 0.000 description 5
- 102000054727 Serum Amyloid A Human genes 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 4
- 206010039705 Scleritis Diseases 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000009850 completed effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 102000018511 hepcidin Human genes 0.000 description 4
- 229940066919 hepcidin Drugs 0.000 description 4
- 108060003558 hepcidin Proteins 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229940071643 prefilled syringe Drugs 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 210000003813 thumb Anatomy 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 230000009184 walking Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010023203 Joint destruction Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960002964 adalimumab Drugs 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229940090048 pen injector Drugs 0.000 description 3
- 208000008494 pericarditis Diseases 0.000 description 3
- -1 phosphoryl groups Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000013442 quality metrics Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 102220117530 rs112626848 Human genes 0.000 description 3
- 102220238658 rs1468529365 Human genes 0.000 description 3
- 102220268018 rs201210997 Human genes 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102100023006 Basic leucine zipper transcriptional factor ATF-like 2 Human genes 0.000 description 2
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 101000903615 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 2 Proteins 0.000 description 2
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100034681 Myeloblastin Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000009921 Rheumatoid Nodule Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- GLGAUBPACOBAMV-DOFZRALJSA-N arachidonylcyclopropylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NC1CC1 GLGAUBPACOBAMV-DOFZRALJSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 2
- 102200148758 rs116840795 Human genes 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 2
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 206010069803 Injury associated with device Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102220349284 c.287A>T Human genes 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940015979 epipen Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 230000010006 flight Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229940062714 humalog mix Drugs 0.000 description 1
- 229940116886 human interleukin-6 Drugs 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 102220210869 rs1057524586 Human genes 0.000 description 1
- 102220220520 rs1060503090 Human genes 0.000 description 1
- 102220206698 rs142514490 Human genes 0.000 description 1
- 102220325921 rs1555376589 Human genes 0.000 description 1
- 102220142694 rs192332456 Human genes 0.000 description 1
- 102200164344 rs63751661 Human genes 0.000 description 1
- 230000009183 running Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006203 subcutaneous dosage form Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000457 tarsus Anatomy 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present technology relates to the field of therapeutic treatment of rheumatoid arthritis. More specifically, the present technology relates to the use of interleukin-6 receptor (IL-6R) antagonists, such as anti-IL-6R antibodies, to treat rheumatoid arthritis.
- IL-6R interleukin-6 receptor
- RA rheumatoid arthritis
- RA is characterized by persistent synovitis and progressive destruction of cartilage and bone in multiple joints.
- the hallmark of the disease is a symmetric polyarthritis characteristically involving the small joints of the hands and feet.
- the inflammatory process can also target other organs, characteristically bone marrow (anemia), eye (scleritis, episcleritis), lung (interstitial pneumonitis, pleuritis), cardiac (pericarditis) and skin (nodules, leukocytoclastic vasculitis).
- Systemic inflammation is characterized by laboratory abnormalities, such as anemia, elevated erythrocyte sedimentation rate, fibrinogen and C-reactive protein (CRP) and by clinical symptoms of fatigue, weight loss, muscle atrophy in affected joint areas.
- CRP C-reactive protein
- anti-CCP anticyclic citrullinated peptide
- the physical function assessment of RA subjects typically takes into account the fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both the upper and lower extremities. These parameters are now widely used by the physicians, clinicians and regulatory agencies to compare the different treatment options offered to RA subjects. In certain instances, two treatments with a similar efficacy profile may have different quality of life or physical function improvement profiles.
- the present disclosure provides methods of treating rheumatoid arthritis in a subject in need thereof.
- the methods include administering to the subject an effective amount of sarilumab (SARI 53191).
- the subject was previously ineffectively treated for rheumatoid arthritis by administering a Janus kinase (JAK)-inhibitor (JAKi).
- JK Janus kinase
- the disclosure provides methods of treating rheumatoid arthritis in a subject that was previously ineffectively treated for rheumatoid arthritis with a JAKi comprising administering an antibody that specifically binds to a human IL-6 receptor and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the three complementarity determining regions (CDRs) found within the amino acid sequence of SEQ ID NO:2 and wherein the VL comprises the three CDRs found within the amino acid sequence of SEQ ID NO:3.
- VH heavy chain variable region
- VL light chain variable region
- the subject is also administered a therapeutically effective amount of methotrexate.
- the antibody is administered subcutaneously at a dose from about 150 mg to about 200 mg once every two weeks.
- methotrexate is administered at a dose from 6 mg to 25 mg every week.
- the antibody comprises three heavy chain CDR (HCDR) sequences comprising SEQ ID NOs: 4, 5, and 6 and three light chain CDR (LCDR) sequences comprising SEQ ID NOs: 7, 8 and 9.
- HCDR heavy chain CDR
- LCDR light chain CDR
- the antibody is sarilumab.
- the subject achieves a DAS28-ESR score below 3.1 after at least 12 weeks of administration of the antibody.
- the subject achieves a clinical disease activity index (CDAI) score below 16 after at least 12 weeks of administration of the antibody.
- CDAI clinical disease activity index
- the subject was previously ineffectively treated for rheumatoid arthritis with a JAKi selected from the group consisting of baricitinib, tofacitinib, and upadacitinib.
- the present disclosure provides methods of treating rheumatoid arthritis in a subject that was previously ineffectively treated for rheumatoid arthritis with a JAKi, comprising administering a disease modifying antirheumatic drug (DMARD) selected from the group consisting of methotrexate, sulfasalazine, hydroxychloroquine and leflunomide, and an antibody that specifically binds to a human IL-6 receptor and comprises a VH and a VL, wherein the VH comprises the three CDRs found within the amino acid sequence of SEQ ID NO: 1 and wherein the VL comprises the three CDRs found within the amino acid sequence of SEQ ID NO:2.
- DMARD disease modifying antirheumatic drug
- the antibody comprises three HCDR sequences comprising SEQ ID NOs: 4, 5, and 6 and 5, and three LCDR sequences comprising SEQ ID NOs: 7, 8 and 9.
- the DMARD that is administered is methotrexate.
- the antibody is administered subcutaneously at a dose from about 150 mg to about 200 mg once every two weeks.
- methotrexate is administered at a dose from 6 mg to 25 mg every week.
- the antibody is sarilumab.
- the subject achieves a DAS28-ESR score below 3.6 after at least 12 weeks of administration of the antibody and DMARD.
- the subject achieves a CDAI score below 16 after at least 12 weeks of administration of the antibody and DMARD.
- the subject was previously ineffectively treated for rheumatoid arthritis with a JAKi selected from the group consisting of baricitinib, tofacitinib, and upadacitinib.
- FIG. 1 graphically depicts DAS-28ESR, CDAI, TJC and SJC in subjects at baseline, and at 4-8 weeks or 12 weeks of JAKi treatment or control.
- FIG. 2 depicts comorbidities and systemic manifestations at start of documentation.
- FIG. 3 depicts an overview of the present study.
- FIG. 4A - FIG. 4B depict the efficacy of sarilumab according to CDAI (A) and HAQ-DI (B) in patients with JAKi (JAKi-IR) or Treatment A (TA) as last prior treatment to sarilumab, in patients who have received either TNFi OR non-TNFi any time in treatment history (bDMARD TH), and in patients who have never received bDMARDs or tsDMARDs (b/tsDMARD naive). Full analysis population is shown. Therefore, baseline (BL) values might differ from baseline values in Table 8.
- the disclosure provides pharmaceutical compositions and methods of using the compositions for the treatment of rheumatoid arthritis (RA) in patients who have been previously treated with one or more JAKis. In some embodiments, patients were previously ineffectively treated with one or more JAKis. In some embodiments, the disclosed compositions and methods are for the improvement of at least one symptom of RA.
- the disclosed compositions include at least one antibody that specifically binds human interleukin-6 receptor (hIL-6R). In some embodiments, the disclosed compositions are effective for improving the physical function and the Quality of Life of subjects suffering from rheumatoid arthritis.
- the present disclosure includes methods that comprise administering to a subject an antibody, or an antigen-binding fragment thereof, that binds specifically to hIL-6R
- hIL-6R means a human cytokine receptor that specifically binds human interleukin-6 (IL-6).
- the antibody that is administered to the subject binds specifically to the extracellular domain of hIL-6R
- the extracellular domain of hIL-6R is shown in the amino acid sequence of SEQ ID NO: 1.
- amino acid sequence of SEQ ID NO: 1 is:
- antibody shall be understood to encompass antibody molecules comprising two immunoglobulin heavy chains and two immunoglobulin light chains (i.e., “full antibody molecules") as well as antigen-binding fragments thereof.
- full antibody molecules immunoglobulin heavy chains and two immunoglobulin light chains
- antigen-binding fragments thereof include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex.
- Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and (optionally) constant domains.
- DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized.
- the DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.
- Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR, V H or VH) and a heavy chain constant region.
- the heavy chain constant region comprises three domains, CH1, CH2 and CH3.
- Each light chain comprises a light chain variable region (abbreviated herein as LCVR, V L or VL) and a light chain constant region.
- the light chain constant region comprises one domain (CL1).
- the V H and V L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR).
- CDRs complementarity determining regions
- Each V H and V L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FRS, CDRS, FR4.
- the FRs of the antibody may be identical to the human germline sequences, or may be naturally or artificially modified.
- An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
- Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated CDR).
- engineered molecules such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, and bivalent nanobodies), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression "antigen-binding fragment," as used herein.
- SMIPs small modular immunopharmaceuticals
- an antigen-binding fragment of an antibody will typically comprise at least one variable domain.
- the variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences.
- the V H and V L domains may be situated relative to one another in any suitable arrangement
- the variable region may be dimeric and contain V H -V H , V H -V L or V L -V L dimers.
- the antigen-binding fragment of an antibody may contain a monomeric VH or VL domain.
- an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain.
- variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present technology include: (i) V H -C H1 ; (ii) V H -C H2 ; (iii) V H -C H3 ; (iv) V H -C H1 -C H2 ; (V) V H -C H1 -C H2 -C H3 ; (vi) V H -C H2 -C H3 ; (vii) V H -CL; (viii) V L -C H1 ; (ix) V L -C H2 ; (x) V L -C H3 ; (xi) V L -C H1 -C H2 ; (xii) V L -C H1 -C H2 ; (xii) V L -C H1 -C H2 -
- variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region.
- a hinge region may consist of at least 2 (e.g, 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule.
- an antigen-binding fragment of an antibody of the present technology may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric V H or V L domain (e.g., by disulfide bond(s)).
- antigen-binding fragments may be monospecific or multispecific (e.g., bispecific).
- a multispecific antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen.
- Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an antibody of the present technology using routine techniques available in the art.
- the constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity.
- the isotype of an antibody may be selected on the basis of whether it is desirable for the antibody to mediate cytotoxicity.
- the antibody or antibody fragment for use in the method of the present technology may be a multispecific antibody, which may be specific for different epitopes of one target polypeptide or may contain antigen-binding domains specific for epitopes of more than one target polypeptide.
- An exemplary bi-specific antibody format that can be used in the context of the present technology involves the use of a first immunoglobulin (Ig) C H3 domain and a second Ig C H3 domain, wherein the first and second Ig C H3 domains differ from one another by at least one amino acid, and wherein at least one amino acid difference reduces binding of the bispecific antibody to Protein A as compared to a bi-specific antibody lacking the amino acid difference.
- Ig immunoglobulin
- the first Ig C H3 domain binds Protein A and the second Ig C H3 domain contains a mutation that reduces or abolishes Protein A binding such as an H95R modification (by IMGT exon numbering; H435R by EU numbering).
- the second C H3 may further comprise an Y96F modification (by IMGT; Y436F by EU).
- the antibodies disclosed herein are human antibodies.
- the term “human antibody,” as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
- the human antibodies featured in the present technology may in various embodiments nonetheless include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in in some embodiments CDR3.
- the term human antibody, as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
- recombinant human antibody is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor et al. (1992) Nucl. Acids Res.
- such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
- an immunoglobulin molecule comprises a stable four chain construct of approximately 150-160 kDa in which the dimers are held together by an interchain heavy chain disulfide bond.
- the dimers are not linked via inter-chain disulfide bonds and a molecule of about 75-80 kDa is formed composed of a covalently coupled light and heavy chain (half-antibody).
- the frequency of appearance of the second form in various intact IgG isotypes is due to, but not limited to, structural differences associated with the hinge region isotype of the antibody.
- a single amino acid substitution in the hinge region of the human IgG4 hinge can significantly reduce the appearance of the second form (Angal et al. (1993) Molecular Immunology 30:105) to levels typically observed using a human IgGl hinge.
- the present technology encompasses in various embodiments antibodies having one or more mutations in the hinge, CH2 or CH3 region which may be desirable, for example, in production, to improve the yield of the desired antibody form.
- the term “specifically binds,” or the like, means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiologic conditions.
- Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like.
- an antibody that specifically binds IL-6R includes antibodies that bind IL- 6R or portion thereof with a KD of less than about 1000 nM, less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM or about 0.5 nM, as measured in a surface plasmon resonance assay.
- Specific binding can be characterized by a dissociation constant of at least about 1x10 -6 M or smaller. In other embodiments, the dissociation constant is at least about 1x10 -7 M, 1x10 -8 M, or 1x10 -9 M.
- Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. An antibody that specifically binds human IL-6R may, however, have cross-reactivity to other antigens, such asIL- 6R molecules from other (non-human) species.
- surface plasmon resonance refers to an optical phenomenon that allows for the analysis of real-time interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcoreTM system (Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).
- KD as used herein, is intended to refer to the equilibrium dissociation constant of an antibody-antigen interaction.
- epitope refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope.
- a single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects.
- Epitopes may be either conformational or linear.
- a conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain.
- a linear epitope is one produced by adjacent amino acid residues in a polypeptide chain.
- an epitope may include moieties of saccharides, phosphoryl groups, or sulfonyl groups on the antigen.
- a “neutralizing” or “blocking” antibody is intended to refer to an antibody that has binding to hIL-6R that results in inhibition of the biological activity of hIL-6. This inhibition of the biological activity of hIL-6 can be assessed by measuring one or more indicators of hIL-6 biological activity known to the art, such as hIL-6-induced cellular activation and hIL-6 binding to hIL-6R (see examples below).
- the anti- IL-6R antibodies disclosed herein may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy and light chain variable domains as compared to the corresponding germline sequences.
- Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases.
- the present technology includes antibodies, and antigen-binding fragments thereof, which are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are back-mutated to the corresponding germline residue(s) or to a conservative amino acid substitution (natural or non-natural) of the corresponding germline residue(s) (such sequence changes are referred to herein as "germline back-mutations").
- a person of ordinary skill in the art can easily produce numerous antibodies and antigen-binding fragments which comprise one or more individual germline back-mutations or combinations thereof.
- all of the framework and/or CDR residues within the VH and/or VL domains are mutated back to the germline sequence.
- only certain residues are mutated back to the germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues found within CDR1, CDR2 or CDR3.
- the antibodies of the present technology may contain any combination of two or more germline back-mutations within the framework and/or CDR regions, i.e., wherein certain individual residues are mutated back to the germline sequence while certain other residues that differ from the germline sequence are maintained.
- antibodies and antigen-binding fragments that contain one or more germline back-mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc.
- Antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present technology.
- the present technology also includes methods involving the use of anti-IL-6R antibodies comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions.
- the present technology includes the use of anti-IL-6R antibodies having HCVR, LCVR, and/or CDR amino acid sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein.
- the anti-IL-6R antibody, or antigen-binding fragment thereof in various embodiments comprises a HCVR, LCVR, and/or CDRs comprising any of the amino acid sequences of the anti-IL-6R antibodies described in U.S. Patent No. 7,582,298, incorporated herein by reference in its entirety.
- the anti-IL-6R antibody or antigen-binding fragment thereof comprises the HCDRs of a HCVR comprising the amino acid sequence of SEQ ID NO: 2 and the LCDRs of a LCVR comprising the amino acid sequence of SEQ ID NO: 3.
- the anti-IL-6R antibody or antigen-binding fragment thereof comprises three HCDRs (i.e., HCDR1, HCDR2 and HCDRS) and three LCDRs (i.e., LCDR1, LCDR2 and LCDRS), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 4; the HCDR2 comprises the amino acid sequence of SEQ ID NO: 5; the HCDRS comprises the amino acid sequence of SEQ ID NO: 6; the LCDR1 comprises the amino acid sequence of SEQ ID NO: 7; the LCDR2 comprises the amino acid sequence of SEQ ID NO: 8; and the LCDRS comprises the amino acid sequence of SEQ ID NO: 9.
- the HCDR1 comprises the amino acid sequence of SEQ ID NO: 4
- the HCDR2 comprises the amino acid sequence of SEQ ID NO: 5
- the HCDRS comprises the amino acid sequence of SEQ ID NO: 6
- the LCDR1 comprises the amino acid sequence of SEQ ID NO: 7
- the LCDR2 comprises the amino acid sequence of SEQ
- the anti-IL-6R antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 10 and a light chain comprising the amino acid sequence of SEQ ID NO: 11.
- the anti-IL-6R antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
- the methods of the present disclosure comprise the use of the anti-IL-6R antibody referred to and known in the art as sarilumab, or a bioequivalent thereof.
- amino acid sequence of SEQ ID NO: 4 is RF TEDDY A.
- amino acid sequence of SEQ ID NO: 5 is ISWNSGRI.
- amino acid sequence of SEQ ID NO: 6 is AKGRDSFDI.
- amino acid sequence of SEQ ID NO: 7 is QGISSW.
- amino acid sequence of SEQ ID NO: 8 is GAS.
- amino acid sequence of SEQ ID NO: 9 is QQANSFPYT.
- amino acid sequence of SEQ ID NO: 10 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- amino acid sequence of SEQ ID NO: 11 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the antibody is sarilumab (SARI S3191).
- bioequivalent refers to a molecule having similar bioavailability (rate and extent of availability) after administration at the same molar dose and under similar conditions (e.g., same route of administration), such that the effect, with respect to both efficacy and safety, can be expected to be essentially same as the comparator molecule.
- Two pharmaceutical compositions comprising an anti-IL-6R antibody are bioequivalent if they are pharmaceutically equivalent, meaning they contain the same amount of active ingredient (e.g., IL- 6R antibody), in the same dosage form, for the same route of administration and meeting the same or comparable standards.
- Bioequivalence can be determined, for example, by an in vivo study comparing a pharmacokinetic parameter for the two compositions. Parameters commonly used in bioequivalence studies include peak plasma concentration (C max ) and area under the plasma drug concentration time curve (AUC).
- the present technology in certain embodiments relates to methods comprising administering to the subject an antibody which comprises the heavy chain variable region comprising sequence SEQ ID NO:2 and the light chain variable region comprising sequence SEQ ID NO:1.
- compositions comprising such antibody, and methods of using these compositions.
- DMARDs Disease modifying antirheumatic drugs
- DMARDs have been classified as synthetic (sDMARD) and biological (bDMARD).
- Synthetic DMARDs include non-exhaustively methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine.
- Biological DMARDs include non-exhaustively adalimumab, golimumab, etanercept, abatacept, infliximab, rituximab, and tocilizumab.
- DMARDs can be administered as follows.
- Methotrexate can be administered from 10 to 25 mg per week orally or intramuscularly.
- methotrexate is administered from 6 to 25 mg/week orally or intramuscularly for subjects who are from the Asia-Pacific region or who are descended from people who are from the Asia-Pacific region.
- the Asia-Pacific region includes Taiwan, South Korea, Malaysia, Philippines, Thailand and India.
- methotrexate is administered at between 6 and 12, 10 and 15, 15 and 20 and 20 and 25 mg per week.
- methotrexate is administered at 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 mg per week.
- Leflunomide can be administered from 10 to 20 mg orally daily. In certain embodiments, leflunomide can be administered at between 10 and 12, 12 and 15, 15 and 17 and 18 and 20 mg per day. In other embodiments, leflunomide is administered at 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 mg per day.
- Sulfasalazine can be administered from 1000 to 3000 mg orally daily. In certain embodiments, sulfasalazine can be administered at between 1000 and 1400, 1400 and 1800, 1800 and 2200, 2200 and 2600, and 2600 and 3000 mg per day.
- sulfasalazine is administered at 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900 or 3000 mg per day.
- Hydroxychloroquine can be administered from 200 to 400 mg orally daily, In certain embodiments, hydroxychloroquine can be administered at between 200 and 240, 240 and 280, 280 and 320, 320 and 360 and 360 and 400 per day.
- hydroxychloroquine can be administered at 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390 or 400 mg per day.
- the methods described herein comprise administering a therapeutically effective amount of an anti-hIL-6R antibody.
- the methods further comprise administering a DMARD to a subject.
- therapeutically effective amount means a dose of anti-hIL-6R antibody and/or a DMARD that results in a detectable improvement in one or more symptoms associated with rheumatoid arthritis or which causes a biological effect (e.g, a decrease in the level of a particular biomarker) that is correlated with the underlying pathologic mechanism(s) giving rise to the condition or symptom(s) of rheumatoid arthritis.
- a dose of anti-hIL-6R antibody and/or one or more DMARDs which causes an improvement in any of the following symptoms or conditions is deemed a "therapeutically effective amount": chronic disease anemia, fever, depression, fatigue, rheumatoid nodules, vasculitis, neuropathy, scleritis, pericarditis, Felly’s syndrome and/or joint destruction.
- the efficacy of the antibody for treating rheumatoid arthritis is typically measured using the standard methods in the field, commonly used by the clinicians and the rheumatologists, for example the DAS-28 and American College of Rheumatism (ACR) parameters, for example the DAS-28 ESR, ACR20, ACR50 and ACR70 parameters.
- ACR DAS-28 and American College of Rheumatism
- a 20 (ACR20), 50 (ACR50) or 70% (ACR70) improvement from baseline can be used to show detectable improvement.
- Another measure used is the clinical disease activity index (CDAI).
- CDAI clinical disease activity index
- the improvement of the physical function of the subjects suffering from rheumatoid arthritis is in various embodiments measured using the standard methods in the field, commonly used by the clinicians and the rheumatologists, namely the HAQ-DI parameter.
- the improvement of the quality of life of the subjects suffering from rheumatoid arthritis is typically measured using the standard methods in the field, commonly used by the clinicians and the rheumatologists, for example the SF36 parameter, and in some embodiments the SF-36 PCS parameter.
- the baseline (also referred to herein as “BL”) is defined as the score obtained by the subject before being administered with the antibody according to the present technology.
- Change from baseline is defined as the difference existing between the score obtained by the subject at baseline and the score obtained by the subject after being administered with the antibody according to the present technology, for example measured at least 24 weeks after the first administration of the antibody, including 24 weeks after the first administration of the antibody.
- the disease activity score can be used to show detectable improvement DAS28 is a composite score of tender joints count based on 28 joints, a swollen joints count based on 28 joints, a general health assessment and a marker of inflammation which can be assessed by measuring C-reactive protein (CRP) levels.
- CRP C-reactive protein
- the disease response can be presented using the European League against Rheumatism (EULAR) response criteria.
- a good response by these criteria is an improvement of greater than 1.2 in DAS28 score with a present score of greater than or equal to 3.2.
- a moderate response is an improvement of greater than 0.6 but less than or equal to 1.2 in DAS28 score and a present score of greater than 3.2.
- Non-response is an improvement of less than 0.6 in DAS28 score and a present score of greater than 5.1.
- DAS28 remission is a DAS28 score of less than 2.6.
- DAS28 is a composite score that includes 4 variables:
- GH General health assessment
- VAS 100 mm visual analogue scale
- the DAS28-ESR can be calculated using the following formula:
- the DAS28-ESR score provides a number indicating the current disease activity of the RA.
- a DAS28-ESR score above 5.1 means high disease activity, whereas a DAS28-ESR score below 3.2 indicates low disease activity and a DAS28-ESR score below 2.6 means disease remission.
- 28TJC/28SJC sum (scored tender/swollen joints)*(number of joints in the full joint set / number of scored tender/swollen joints).
- the number of joints in the full joint set is defined as (28 - number of replaced or fused joints) and the scored joints refer to those with an answer (0 - no pain, 1- pain).
- DAS28-ESR is considered as missing if one of the components is missing.
- VAS Visual Analog Score
- the VAS is a measure to assess subject-related rheumatoid arthritis severity. Subject makes a vertical mark through each of two lines which best describes the amount of pain due to rheumatoid arthritis. Range from no pain to most severe pain. ACR20
- a subject To be classified as an ACR20 responder, a subject must achieve 20% improvement compared with baseline, in both TJC and SJC, as well as 20% improvement in at least 3 out of the 5 remaining ACR components: physician’s global assessment of disease activity, subject’s global assessment of disease activity, pain, HAQ-DI, and CRP.
- ACR50 is defined as the event of achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 out of the 5 remaining ACR components.
- ACR70 is defined as the event of achieving at least 70% improvement in both TJC and SJC and at least 70% improvement in at least 3 out of the 5 remaining ACR components.
- TJC Tender Joint Count
- a total of 68 joints are assessed for tenderness.
- a formal count of the joints is performed by a trained assessor.
- Joint tenderness is defined as pain induced by the pressure of the joints, exerted by the assessor’s thumb and index finger.
- the assessor classifies each joint as painful (yes/no) and swollen (yes/no).
- a score of 0/1 is given to each tender joint with 0 representing no pain and 1 representing pain.
- the tender joint count ranges from 0 to 68 where 0 is considered the best and 68 the worst.
- SJC Swollen Joint Count
- Subject global assessments of their current disease activity is rated on an anchored 100 mm horizontal VAS where 0 is considered the best disease activity (no disease activity) and 100 the worst (most disease activity).
- Subjects are requested to indicate their pain intensity due to their RA using a 100 mm horizontal VAS where 0 is considered “No pain” and 100 “the worst pain you can imagine”.
- HAQ-DI Health Assessment Questionnaire Disease Index
- the HAQ-DI is a standardized questionnaire developed for use in RA.
- the HAQ-DI with the past week as the time frame, focuses on whether the respondent “is able to... ” do the activity and covers 8 categories in 20 items: dressing and grooming, arising, eating, walking, hygiene, reach, grip and activities, for which there are at least 2 questions by category.
- HAQ-DI score cannot be calculated validly when there are scores for less than 6 of the 8 categories. HAQ-DI scoring ranges between 0 and 3. A high HAQ-DI score has been found to be a strong predictor of morbidity and mortality in RA. A 0.22 unit difference is considered clinically meaningful.
- CRP High sensitivity CRP is assessed centrally. Since CRP levels are directly correlated with Interleukin 6 (IL-6) receptor activity, it is expected that active dose regimens has a dramatic lowering effect on CRP levels. Therefore, during the study, post-dosing CRP remains blinded to the investigators, the sponsor and the subjects.
- IL-6 Interleukin 6
- the ACR components are further described in Table 1.
- SF-36V2 The QualityMetric’s SF-36v2® Health Survey is a multi-purpose, short-form health survey with 36 questions. It yields scores for eight domains (Physical Functioning, Role-Physical, Bodily pain, General health, Vitality, Social Functioning, Role-Emotional, and Mental Health, where each domain is scored from 0 to 100 and where higher scores indicate better health and well-being), as well as two summary measures of physical and mental health: the physical component summary (PCS) and mental component summary (MCS).
- PCS physical component summary
- MCS mental component summary
- the Abbreviated Item Content is as follows:
- 3a Vigorous activities such as running, lifting heavy objects, or participating in strenuous sports
- 3b Moderate activities such as moving a table, pushing a vacuum cleaner, bowling, or playing golf
- the PCS and MCS summary measure scores are computed if at least 50% of the component scales are available.
- the scale scores are computed if at least 50% of items are available within the corresponding scale. The missing items are imputed by the mean of available items.
- Step 1 Item recoding, for the 10 items that require recoding,
- Step 2 Computing scale scores by summing across items in the same scale (raw scale scores); and,
- Step 3 Transforming raw scale scores to a 0-100 scale (transformed scale).
- All 36 items should be checked for out-of-range values prior to assigning the final item value. All out-of-range values should be recoded as missing data.
- a scale score is calculated if a respondent answered at least half of the items in a multiitem scale (or half plus one in the case of scales with an odd number of items).
- the recommended algorithm substitutes a person-specific estimate for any missing item when the respondent answered at least SO percent of the items in a scale.
- a psychometrically sound estimate is the average score, across completed items in the same scale, for that respondent For example, if a respondent leaves one item in the 5 -item mental Health scale blank, one must substitute the respondent’s average score (across the 4 completed mental health items) for that one item. When estimating the respondent’s average score, use the respondent’s final item values.
- a raw score is computed for each scale. This score is a simple algebraic sum of responses for all items in that scale.
- the score can be calculated. If the respondent did not answer at least 50% of the items, the score for that scale should be set to missing.
- the next step involves transforming each raw score to a 0 to 100 scale using the following formula:
- Transformed scale [(actual raw score - lowest possible raw score) / possible raw score range] x 100
- This transformation converts the lowest and highest possible scores to zero and 100, respectively.
- the score of each of the 36 items is collected in CRF (case report form). Then, a SAS (Statistical Analysis System) code (e.g. the one provided by the QualityMetric survey) is used to calculate the eight scales, the two summary measure scores and the standardized summary scores. The PCS and MCS summary measure scores are computed if at least 50% of the component scales are available. The scale scores are computed if at least 50% of items are available within the corresponding scale. The missing items are imputed by the mean of available items.
- SAS Statistical Analysis System
- Step 1 Item recoding, for the 10 items that require recoding
- Step 2. Computing scale scores by summing across items in the same scale (raw scale scores);
- Step 3 Transforming raw scale scores to a 0-100 scale (transformed scale)
- Step 5 Compute Z-Scores
- Step 6 Convert Z-score to Norm Based scores for domains PCS: Compute aggregate PCS score using a specific weighted formula, convert this into a Norm based score
- MCS Compute aggregate MCS score using a specific weighted formula, convert this into a Norm based score
- All 36 items should be checked for out-of-range values prior to assigning the final item value. All out-of-range values should be recoded as missing data.
- a scale score is calculated if a respondent answered at least half of the items in a multiitem scale (or half plus one in the case of scales with an odd number of items).
- the recommended algorithm substitutes a person-specific estimate for any missing item when the respondent answered at least 50 percent of the items in a scale.
- a psychometrically sound estimate is the average score, across completed items in the same scale, for that respondent For example, if a respondent leaves one item in the 5-item mental Health scale blank, one must substitute the respondent’s average score (across the 4 completed mental health items) for that one item. When estimating the respondent’s average score, use the respondent’s final item values.
- a raw score is computed for each scale. This score is a simple algebraic sum of responses for all items in that scale.
- the score can be calculated. If the respondent did not answer at least 50% of the items, the score for that scale should be set to missing.
- the next step involves transforming each raw score to a 0 to 100 scale using the following formula:
- Transformed scale [(actual raw score - lowest possible raw score) / possible raw score range] x 100.
- the clinical disease activity index (CDAI) is an established instrument to measure disease activity in rheumatoid arthritis (RA).
- the CDAI is composite index calculated as the sum of five outcome parameters:
- V AS visual analogue scale
- CDAI TEN28 + SWJ28 + PGAVAS + INWAS.
- CDAI does not include the C-Reactive Protein. An immediate scoring is, therefore, possible in a clinical trial.
- the CDAI score is interpreted as follows:
- a therapeutically effective amount of anti-hIL-6R antibody that is administered to the subject will vary depending upon the age and the size (e.g, body weight or body surface area) of the subject as well as the route of administration and other factors well known to those of ordinary skill in the art.
- the dose of anti-hIL-6R antibody administered to the subject is from about 10 mg to about 500 mg.
- the present technology includes methods wherein about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg
- the hIL-6R antibody is administered at 100-150 mg per week. In another embodiment, the hIL-6R antibody is administered at 100-200 mg per ever two weeks. In other embodiments, the hIL-6R antibody is administered at about 100 or about 150 mg per week. In other embodiments, the hIL-6R antibody is administered at about 100, 150 or 200 mg per every two weeks. “Once every two weeks” has the same meaning as “q2w” or “once per two weeks”, i.e. that the antibody is administered once in a two-week period of time. According to certain embodiments, the antibody is administered subcutaneously. In certain embodiments, the antibody is administered at about 100 mg, 150 mg or about 200 mg once every two weeks. In this context, “about” refers to an amount within 5% of the stated amount For example, “about 100 mg” is a range of between 95 and 105 mg. According to certain embodiments, the antibody is administered subcutaneously.
- the amount of anti-hIL-6R antibody that is administered to the subject may be expressed in terms of milligrams of antibody per kilogram of subject body weight (i.e., mg/kg).
- the methods of the present technology include administering an anti-hIL-6R antibody to a subject at a daily dose of about 0.01 to about 100 mg/kg, about 0.1 to about 50 mg/kg, or about 1 to about 10 mg/kg of subject body weight
- the antibody is administered as an aqueous buffered solution at about pH 6.0 containing
- the antibody is administered as an aqueous buffered solution at pH
- the antibody is administered as an aqueous buffered solution at about pH 6.0 containing about 21 mM histidine, about 45 mM arginine, about 0.2% (w/v) polysorbate 20, about 5% (w/v) sucrose, and about 131.6 mg/mL of the antibody.
- the antibody is administered as an aqueous buffered solution at about pH 6.0 containing about 21 mM histidine, about 45 mM arginine, about 0.2% (w/v) polysorbate 20, about 5% (w/v) sucrose; and about 175 mg/mL of the antibody.
- the antibody is administered as an aqueous buffered solution at pH
- the antibody is administered as an aqueous buffered solution at pH
- the antibody is administered as an aqueous buffered solution at pH 6.0 containing
- the antibody is administered as an aqueous buffered solution at pH 6.0 containing
- the methods of the present technology include administering multiple doses of an anti- hIL-6R antibody to a subject over a specified time course.
- the anti-hIL-6R antibody can be administered about 1 to 5 times per day, about 1 to 5 times per week, about 1 to 5 times per month or about 1 to 5 times per year.
- the methods of the present technology include administering a first dose of anti-hIL-6R antibody to a subject at a first time- point, followed by administering at least a second dose of anti-hIL-6R antibody to the subject at a second time-point.
- the first and second doses may contain the same amount of anti-hIL-6R antibody.
- the first and second doses may each contain about 10 mg to about 500 mg, about 20 mg to about 300 mg, about 100 mg to about 200 mg, or about 100 mg to about 150 mg of the antibody.
- the time between the first and second doses may be from about a few hours to several weeks.
- the second time-point ⁇ i.e. , the time when the second dose is administered
- the second time-point can be about 1 hour, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 2 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 14 weeks or longer after the first time-point.
- the second time-point is about 1 week or about 2 weeks. Third and subsequent doses may be similarly administered throughout the course of treatment of the subject
- the present technology provides methods of using therapeutic compositions comprising anti-IL-6R antibodies or antigen-binding fragments thereof and/or one or more DMARDs.
- the therapeutic compositions of the present technology will be administered with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like.
- suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like.
- suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like.
- a multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.
- formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTINTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. “Compendium of excipients for parenteral formulations” PDA (1998) J Pharm Sci Technol 52:238-311.
- the dose may vary depending upon the age and the weight of a subject to be administered, target disease, conditions, route of administration, and the like.
- Various delivery systems are known and can be used to administer the pharmaceutical composition of the present technology, e.g., encapsulation in liposomes, microparticles, microcapsules, receptor mediated endocytosis (see, e.g., Wu et al. (1987) J. Biol. Chem. 262:4429-4432).
- Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes.
- composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
- the hIL-6R antibody can be administered subcutaneously.
- the DMARD can be administered orally or intramuscularly.
- the pharmaceutical composition can also be delivered in a vesicle, in particular a liposome (see Langer (1990) Science 249: 1527-1533).
- the pharmaceutical composition can be delivered in a controlled release system, for example, with the use of a pump or polymeric materials.
- a controlled release system can be placed in proximity of the composition’s target, thus requiring only a fraction of the systemic dose.
- the injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, local injection, drip infusions, etc. These injectable preparations may be prepared by methods publicly known. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections.
- aqueous medium for injections there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (SO mol) adduct of hydrogenated castor oil)], etc.
- an alcohol e.g., ethanol
- a polyalcohol e.g., propylene glycol, polyethylene glycol
- a nonionic surfactant e.g., polysorbate 80, HCO-50 (polyoxyethylene (SO mol) adduct of hydrogenated castor oil
- oily medium there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc.
- a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc.
- the antibody is typically formulated as described herein and in international publication number WO2011/085158, incorporated herein by reference in its entirety.
- the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients.
- dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
- the amount of the DMARD contained is generally about 5 to 3000 mg per dosage form in an oral unit dose depending on the specific DMARD used.
- the amount of the hIL-6R antibody contained is generally about 100 to 200 mg per subcutaneous dosage form.
- the anti-hIL-6R antibody (or pharmaceutical formulation comprising the antibody) can be administered to the subject using any acceptable device or mechanism.
- the administration can be accomplished using a syringe and needle or with a reusable pen and/or autoinjector delivery device.
- the methods of the present technology include the use of numerous reusable pen and/or autoinjector delivery devices to administer an anti-hIL-6R antibody (or pharmaceutical formulation comprising the antibody).
- Examples of such devices include, but are not limited to AUTOPENTM (Owen Mumford, Inc., Woodstock, UK), DISETRONICTM pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75/25TM pen, HUMALOGTM pen, HUMALIN 70/30TM pen (Eli Lilly and Co., Indianapolis, IN), NOVOPENTM I, ⁇ and ⁇ (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIORTM (Novo Nordisk, Copenhagen, Denmark), BDTM pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPENTM, OPTIPEN PROTM, OPTIPEN STARLETTM, and OPTICLIKTM (sanofi- aventis, Frankfurt, Germany), to name only a few.
- Examples of disposable pen and/or autoinjector delivery devices having applications in subcutaneous delivery of a pharmaceutical composition of the present technology include, but are not limited to the SOLOSTARTM pen (sanofi-aventis), the FLEXPENTM (Novo Nordisk), and the KWIKPENTM (Eli Lilly), the SURECLICKTM Autoinjector (Amgen, Thousand Oaks, CA), the PENLETTM (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.P.), and the HUMIRATM Pen (Abbott Labs, Abbott Park, IL), to name only a few.
- microinfusor means a subcutaneous delivery device designed to slowly administer large volumes (e.g, up to about 2.5 mL or more) of a therapeutic formulation over a prolonged period of time (e.g., about 10, 15, 20, 25, 30 or more minutes). See, e.g., U.S. 6,629,949; US 6,659,982; and Meehan etal, J. Controlled Release 46:107-116 (1996).
- Microinfusors are particularly useful for the delivery of large doses of therapeutic proteins contained within high concentration (e.g., about 100, 125, 150, 175, 200 or more mg/mL) and/or viscous solutions.
- the antibody is administered with a prefilled syringe.
- the antibody is administered with a prefilled syringe containing a safety system.
- the safety system prevents an accidental needlestick injury.
- the antibody is administered with a prefilled syringe containing an ERISTM safety system (West Pharmaceutical Services Inc.). See also U.S. patent numbers 5,215,534 and 9,248,242, incorporated herein by reference in their entireties.
- the antibody is administered with an auto-injector.
- the antibody is administered with an auto-injector featuring the PUSHCLICKTM technology (SHL Group).
- the auto-injector is a device comprising a syringe that allows for administration of a dose of the composition and/or antibody to a subject See also U.S. patent numbers 9,427,531 and 9,566,395, incorporated herein by reference in their entireties.
- the present technology includes methods of treating rheumatoid arthritis which comprise administering to a subject in need of such treatment an anti-hIL-6R antibody in combination with at least one additional therapeutic agent.
- additional therapeutic agents which can be administered in combination with an anti-hIL-6R antibody in the practice of the methods of the present technology include, but are not limited to DMARDs, and any other compound known to treat, prevent, or ameliorate rheumatoid arthritis in a human subject
- Specific, non-limiting examples of additional therapeutic agents that may be administered in combination with an anti- hIL-6R antibody in the context of a method of the present technology include, but are not limited to methotrexate, sulfasalazine, hydroxychloroquine and leflunomide.
- the additional therapeutic agent(s) can be administered concurrently or sequentially with the anti-hlL- 6R antibody.
- a pharmaceutical formulation can be made which contains both an anti-hIL-6R antibody and at least one additional therapeutic agent.
- the amount of the additional therapeutic agent that is administered in combination with the anti- hIL-6R antibody in the practice of the methods of the present technology can be easily determined using routine methods known and readily available in the art.
- compositions comprising any of the following:
- a composition comprising between 100 and 150 mg of sarilumab (SA153191) and 10-25 mg of methotrexate.
- a composition comprising between 100 and 200 mg of sarilumab (SA153191) and 10-25 mg of methotrexate.
- a composition comprising between 100 and 150 mg of sarilumab (SA153191) and 6-25 mg of methotrexate.
- a composition comprising between 100 and 200 mg of sarilumab (SA153191) and 6-25 mg of methotrexate.
- a composition comprising between 100 and 150 mg of sarilumab (SA153191) and 10-20 mg of leflunomide.
- a composition comprising between 100 and 200 mg of sarilumab (SA153191) and 10-20 mg of leflunomide.
- a composition comprising between 100 and 150 mg of sarilumab (SA153191) and 1000- 3000 mg of sulfasalazine.
- a composition comprising between 100 and 200 mg of sarilumab (SA153191) and 1000- 3000 mg of sulfasalazine.
- a composition comprising between 100 and 150 mg of sarilumab (SA153191) and 200- 400 mg of hydroxychloroquine.
- a composition comprising between 100 and 200 mg of sarilumab (SA153191) and 200- 400 mg of hydroxychloroquine.
- the disclosure of the present technology provides for methods of improving symptoms associated with rheumatoid arthritis comprising any of the following:
- a method comprising administering between 100 and 150 mg of sarilumab (SA153191) and 10-25 mg of methotrexate per week to a subject in need thereof.
- a method comprising administering between 100 and 200 mg of sarilumab (SA153191) every two weeks and 10-25 mg of methotrexate per week to a subject in need thereof.
- a method comprising administering between 100 and 150 mg of sarilumab (SA153191) and 6-25 mg of methotrexate per week to a subject in need thereof.
- a method comprising administering between 100 and 200 mg of sarilumab (SA153191) every two weeks and 6-25 mg of methotrexate per week to a subject in need thereof.
- a method comprising administering between 100 and 150 mg of sarilumab (SA153191) per week and 10-20 mg of leflunomide per day to a subject in need thereof.
- a method comprising administering between 100 and 200 mg of sarilumab (SA153191) every two weeks and 10-20 mg of leflunomide per day to a subject in need thereof.
- a method comprising administering between 100 and 150 mg of sarilumab (SA153191) per week and 1000-3000 mg of sulfasalazine per day to a subject in need thereof.
- SA153191 sarilumab
- a method comprising administering between 100 and 200 mg of sarilumab (SA153191) every two weeks and 1000-3000 mg of sulfasalazine per day to a subject in need thereof.
- SA153191 sarilumab
- a method comprising administering between 100 and 150 mg of sarilumab (SA153191) per week and 200-400 mg of hydroxychloroquine per day to a subject in need thereof.
- a method comprising administering between 100 and 200 mg of sarilumab (SA153191) every two weeks and 200-400 mg of hydroxychloroquine per day to a subject in need thereof.
- the present disclosure includes methods of treating rheumatoid arthritis by administering to a subject in need of such treatment a therapeutically effective amount of an antibody or antibody binding fragment thereof which specifically binds to hIL-6R and, optionally, a therapeutically effective amount of one or more DMARDs, wherein the level of one or more RA-associated biomarkers in the subject is modified (e.g. , increased, decreased, etc. , as the case may be) following administration.
- the present technology includes methods for decreasing an RA- associated biomarker in a subject by administering to the subject a therapeutically-efifective amount of an antibody or antigen-binding fragment thereof which specifically binds to hIL-6R and, optionally, a therapeutically effective amount of one or more DMARDs.
- RA-associated biomarkers include, but are not limited to, e.g., high-sensitivity C-reactive protein (hsCRP), serum amyloid A (SAA), erythrocyte sedimentation rate (ESR), serum hepcidin, interleukin-6 (IL-6), and hemoglobin (Hb).
- hsCRP high-sensitivity C-reactive protein
- SAA serum amyloid A
- ESR erythrocyte sedimentation rate
- IL-6 interleukin-6
- Hb hemoglobin
- an increase or decrease in an RA-associated biomarker can be determined by comparing the level of the biomarker measured in the subject at a defined time point after administration of the anti-IL-6R antibody to the level of the biomarker measured in the subject prior to the administration (i.e., the "baseline measurement").
- the defined time point at which the biomarker can be measured can be, e.g., at about 4 hours, 8 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 15 days, 20 days, 35 days, 40 days or more after administration of the anti-hIL-6R antibody.
- a subject may exhibit a decrease in the level of one or more of hsCRP, SAA, ESR and/or hepcidin following administration of an anti-hIL-6R antibody to the subject
- the subject may exhibit one or more of the following: (i) a decrease in hsCRP by about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more; (ii) a decrease in SAA by about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more; (iii) a decrease in ESR by about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or more; and/or (iv) a decrease in hepcidin by about 30%, 35%, 40%, 45%
- a subject may exhibit an increase in the level of one or more of Hb or IL-6 following administration of an anti-hIL-6R antibody and, optionally, one or more DMARDs to the subject.
- the subject may exhibit one or more of the following: (v) an increase in Hb by about 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0% or more; and/or (vi) an increase in IL-6 by about 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800% or more.
- the present technology includes methods for determining whether a subject is a suitable subject for whom administration of an anti-hIL-6R antibody would be beneficial. For example, if an individual, prior to receiving an anti-hIL-6R antibody and/or one or more DMARDs, exhibits a level of an RA-associated biomarker which signifies the disease state, the individual is therefore identified as a suitable subject for whom administration of an anti-hIL-6R antibody would be beneficial.
- an individual may be identified as a good candidate for anti-hIL-6R/DMARD therapy if the individual exhibits one or more of the following: (i) a level of hsCRP greater than about 4 mg/L (e.g., about 4.5 mg/L, about 5.0 mg/L, about 5.5 mg/L, about 6.0 mg/L, about 7.0 mg/L, about 10.0 mg/L, about 15.0 mg/L, about 20.0 mg/L, or more); (ii) a level of SAA greater than about 3800 ng/mL (e.g., about 4000 ng/mL, 4500 ng/mL, about 5000 ng/mL, about 5500 ng/mL, about 6000 ng/mL, about 10,000 ng/mL, about 20,000 ng/mL, about 25,000 ng/mL, about 30,000 ng/mL, about 35,000 ng/mL, about 40,000 ng/mL, about 45,000 ng/
- subject means a human subject or human patient
- the methods and compositions described herein are administered to specific subject populations.
- These populations include subjects that have previously been treated for rheumatoid arthritis with treatment regimens other than an anti-hIL-6R antibody.
- treatment regimens include DMARDs such as anti-TNF-a therapy (TNFi), e.g., biologic anti-TNF- ⁇ treatment regimens, and/or JAK-inhibitor (JAKi) therapy.
- TNFi anti-TNF-a therapy
- JAK-inhibitor JAK-inhibitor
- Biologic anti-TNF-a antagonists include etanercept, infliximab, adalimumab, golimumab and certolizumab pegol.
- JAK-inhibitors include baricitinib, tofacitinib, and upadacitinib.
- DMARDs used in this therapy include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide.
- the DMARDs may be administered alone or in combination with another therapy that is not an anti-hIL-6R antibody.
- the previous treatment regimen was methotrexate.
- the subject has been administered both anti-TNF-a and other DMARD therapies.
- the previous treatment regimen was a JAKi.
- the subject has been administered both JAKi and other DMARD therapies.
- a subject who is considered “ineffectively treated” is a subject who in various embodiments either has shown to be intolerant to the one or more previous treatment regimens, and/or a subject who has shown an inadequate response to the one or more previous treatment regimen, typically a subject who is still considered to present with, or to have, active rheumatoid arthritis despite the previous one or more treatment regimen administered.
- the “Active rheumatoid arthritis” is typically defined as:
- the subject who was previously ineffectively treated for rheumatoid arthritis by administering at least one DMARD different from the antibody, is a subject who was previously ineffectively treated for rheumatoid arthritis by administering a DMARD selected from the group consisting of methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine.
- a DMARD selected from the group consisting of methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine.
- the DMARD is methotrexate.
- the subject who was previously ineffectively treated for rheumatoid arthritis by administering one or more DMARD different from the antibody, is a subject who had an inadequate response or intolerance to methotrexate.
- the one or more DMARD is/are not administered anymore to the subject, and the antibody is in various embodiments administered alone, in monotherapy to the subject.
- “monotherapy” means that the subject receiving the antibody is not administered with any other DMARD (or other treatment regimen) in course of administration with the antibody.
- the subject who was previously ineffectively treated for rheumatoid arthritis by administering treatment regimens other than the combination of an anti-hIL-6R antibody and, optionally, one or more DMARDs, is a subject who was previously ineffectively treated for rheumatoid arthritis by administering an anti-TNF-a treatment regimen.
- the subject who was previously ineffectively treated for rheumatoid arthritis by administering treatment regimens other than the combination of an anti-hIL-6R antibody and, optionally, one or more DMARDs, is a subject who was previously ineffectively treated for rheumatoid arthritis by administering a JAKi treatment regimen.
- the subject who was previously ineffectively treated for rheumatoid arthritis by administering one or more treatment regimens different from the antibody, is a subject who had an inadequate response or intolerance to an anti-TNF-a treatment regimen.
- the subject who was previously ineffectively treated for rheumatoid arthritis by administering one or more treatment regimens different from the antibody, is a subject who had an inadequate response or intolerance to a JAKi treatment regimen.
- the one or more treatment is/are not administered anymore to the subject, and the antibody is in various embodiments administered alone, in monotherapy to the subject
- the subject is intolerant to the DMARD and/or other treatment regimen due to one or more physical reactions, conditions or symptoms from the treatment with the DMARD or other treatment regimen.
- Physical reactions, conditions or symptoms can include allergies, pain, nausea, diarrhea, azotemia, bleeding of the stomach, intestinal bleeding, canker sores, decreased blood platelets, perforation of the intestine, bacterial infection, inflammation of gums or mouth, inflammation of the stomach lining or intestinal lining, bacterial sepsis, stomach ulcer, intestinal ulcer, sun sensitive skin, dizziness, loss of appetite, low energy, and vomiting.
- intolerance can be determined by the subject or by a medical professional upon examination of the subject.
- the DMARD is selected from the group consisting of methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine.
- the DMARD is methotrexate.
- the DMARD is an anti- TNF ⁇ treatment regimen.
- the DMARD is a JAKi treatment regimen.
- the subject suffers from diminishment in quality of life due to RA.
- subjects suffering from diminishment in quality of life due to RA score as more severe than average on a metric selected from Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L), Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID), Work Days Missed Due to Arthritis, Work Productivity Reduced by > 50% Due to Arthritis, Rate of Arthritis Interference With Work Productivity, House Work Days Missed Due to Arthritis, Days With Household Work Productivity Reduced by > 50% Due to Arthritis, Days With Family/Social/Leisure Activities Missed Due to Arthritis, Days With Outside Help Hired Due to Arthritis, Rate of RA Interference With Household Work Productivity, Morning Stiffness VAS, Individual ACR Component - TJC and SJC, Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS
- subjects who score as more severe than average on one or more metrics listed above have a score that is more severe than the baseline value for the metric.
- a subject having a score of baseline value or more severe than baseline value on one or more metrics listed above, after receiving treatment indicates that the subject is an inadequate responder to the treatment
- a subject having a score more severe than baseline value on one or more metrics listed above, after receiving treatment indicates that the subject is an inadequate responder to the treatment.
- the subjects who have scores for metrics that are more severe than the baseline value for the metric listed above have scores that are at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100% more severe than baseline.
- the therapies may be performed sequentially in any order or simultaneously. In certain embodiments, these therapies have been received by the subject within 2 years prior to receiving the combination of an anti-hIL-6R antibody and one or more DMARDs. In other embodiments, these therapies have been received within 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 years prior to receiving the combination of an anti-hIL-6R antibody and one or more DMARDs.
- the methods and compositions described herein are administered to specific subject populations that have received one or more of the treatment regimens described above wherein these treatments have not been effective.
- a treatment has not been effective when one or more dose does not result in a detectable improvement in one or more symptoms associated with rheumatoid arthritis or which does not cause a biological effect (e.g, a decrease in the level of a particular biomarker) that is correlated with the underlying pathologic mechanism(s) giving rise to the condition or symptom(s) of rheumatoid arthritis.
- a treatment which does not cause an improvement in any of the following symptoms or conditions is deemed ineffective: chronic disease anemia, fever, depression, fatigue, rheumatoid nodules, vasculitis, neuropathy, scleritis, pericarditis, Felly’s syndrome and/or joint destruction.
- a detectable improvement can also be detected using the American College of Rheumatism (ACR) rheumatoid arthritis classification criteria. For example, a 20 (ACR20), 50 (ACR50) or 70% (ACR70) improvement from baseline can be used to show detectable improvement. A detectable improvement can also be shown by measuring an improvement in any of the components of the DAS28 score.
- ACR American College of Rheumatism
- This example shows that treatment with an antibody of the present technology is effective in treating RA subjects that were ineffectively treated with JAKi.
- DAS28-ESR decreased from 5.0 ⁇ 1.46 to 3.0 ⁇ 1.44 and CDAI from 26.7 ⁇ 13.79 to 13.6 ⁇ 11.4.
- Boolean remission was observed in 9.5% of subjects at week 12.
- HAQ-DI improved from 1.3 at baseline to 1.1 at week 12 (Table 4).
- CDAI improvement was similar for autoantibody-positive (RF + and/or ACPA + ; CDAI -12.5 at week 12) compared to -negative subjects (CDAI -15.4 at week 12) (see Table 6).
- Subjects switching from JAKi to sarilumab (n 32), were more severely affected, had longer disease duration and received more prior treatments than subjects switched from another compound. Similar efficacy was observed among subjects that switched from JAKi to sarilumab vs subjects switched from other DMARDs; disease activity outcome measures including DAS28, CDAI, TJC, SJC and global assessments improved consistently (FIG. 1).
- DAS28-ESR disease activity score in 28 joints involving erythrocyte sedimentation rate
- CDAI clinical disease activity index
- TJC tender joint counts
- SJC swollen joint counts
- HAQ-DI health assessment questionnaire disability index.
- compositions and methods of the present disclosure are not to be limited in scope by the specific embodiments describe herein. Indeed, various modifications of the present technology in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
- IA interim analysis validates and expanding the insights into safety and effectiveness of sarilumab in patients with IR to last prior treatment JAKi (JAKi-IR). Additional subgroup analysis included patients who have received either TNF-inhibitor (TNFi) or non-TNFi bDMARD anytime in treatment history (bDMARD TH), and patients who have never received bDMARDs or targeted synthetic DMARDs (tsDMARDs) (b/tsDMARD naive).
- TNFi TNF-inhibitor
- tsDMARDs targeted synthetic DMARDs
- sarilumab administered in regular care demonstrated improvement of RA disease activity in patients with IR to JAKi as well as in bDMARD pretreated and b/tsDMARD naive patients.
- the fact that no substantial change in physical function was observed might be due to lower baseline HAQ-DI scores in PROSARA compared to the phase III trials 1-3 and the relatively short observation time.
- Table 8 Baseline data regarding patient characteristics, disease activity and serostatus. Baseline population is shown. Therefore, baseline values might differ from baseline values in FIG. 4.
- Kevzara (sarilumab) - summary of product characteristics, 2021. Available: https://www.ema.europa.eu/en/documents/product-information/kevzara-epar- product-information en. pdf [Accessed 18 Feb 2021],
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063030065P | 2020-05-26 | 2020-05-26 | |
US202163155125P | 2021-03-01 | 2021-03-01 | |
PCT/IB2021/054546 WO2021240369A1 (en) | 2020-05-26 | 2021-05-25 | Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4157872A1 true EP4157872A1 (de) | 2023-04-05 |
Family
ID=85382421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21729026.1A Pending EP4157872A1 (de) | 2020-05-26 | 2021-05-25 | Zusammensetzungen mit einem antikörper gegen den interleukin-6-rezeptor zur behandlung von rheumatoider arthritis und verfahren zur verwendung davon |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP4157872A1 (de) |
-
2021
- 2021-05-25 EP EP21729026.1A patent/EP4157872A1/de active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210230719A1 (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
US20180296670A1 (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
TWI747885B (zh) | 用於治療類風濕性關節炎之組成物及方法 | |
US20230174657A1 (en) | Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same | |
US20200399380A1 (en) | Compositions and methods for treating pain in subjects with rheumatoid arthritis | |
EP4157872A1 (de) | Zusammensetzungen mit einem antikörper gegen den interleukin-6-rezeptor zur behandlung von rheumatoider arthritis und verfahren zur verwendung davon | |
US20230192871A1 (en) | Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis | |
RU2822089C2 (ru) | Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита | |
NZ746988B2 (en) | Compositions and methods for treating rheumatoid arthritis | |
IL265949A (en) | Preparations for the treatment of rheumatoid arthritis and methods of using them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20221223 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ALBRECHT, INKA |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40091694 Country of ref document: HK |